Why Are Investors Ignoring Vertex's Good News?

Why Are Investors Ignoring Vertex's Good News?

Vertex Pharmaceuticals' (NASDAQ: VRTX) woes began about a year ago when it announced the failure of an alpha-1 antitrypsin deficiency (AATD) candidate in clinical trials. Since that first problem, Vertex shares have dropped 33%. Vertex boasts a billion-dollar cystic fibrosis (CF) business.